A5049169459- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Screening and Detection
- Immunodeficiency and Autoimmune Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Liver Diseases and Immunity
- Diverticular Disease and Complications
- Biosimilars and Bioanalytical Methods
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Celiac Disease Research and Management
- Adolescent and Pediatric Healthcare
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Diagnosis and treatment of tuberculosis
- Mycobacterium research and diagnosis
- Autoimmune and Inflammatory Disorders Research
- Pregnancy and Medication Impact
- Gastrointestinal motility and disorders
- Pharmaceutical studies and practices
- Chronic Lymphocytic Leukemia Research
- IL-33, ST2, and ILC Pathways
University of Chicago
2016-2025
University of Chicago Medical Center
2014-2025
Planetary Science Institute
2025
University of Calgary
2007-2024
Icahn School of Medicine at Mount Sinai
2009-2024
Western University
2024
Children's Hospital of Philadelphia
2024
University of Pennsylvania
2024
Roche (Switzerland)
2024
UCB Pharma (Belgium)
2024
Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the preferred approach to management of adults with UC and represent official practice recommendations American College Gastroenterology. The scientific evidence for these was evaluated using Grading Recommendations Assessment, Development, Evaluation (GRADE) process. In instances where not appropriate GRADE, but there consensus significant clinical merit, “key concept” statements were developed expert...
Abstract Background The Crohn’s & Colitis Foundation’s Cost of Inflammatory Bowel Disease (IBD) Care Initiative seeks to quantify the wide-ranging health care costs affecting patients living with IBD. We aimed (1) describe annualized direct and indirect for disease (CD) or ulcerative colitis (UC), (2) determine longitudinal drivers these costs, (3) characterize cost newly diagnosed patients. Methods analyzed Optum Research Database from years 2007 2016, representing commercially insured...
Clonidine and ICI 106270 are centrally acting antihypertensive agents which act through stimulation of medullary alpha-2 adrenoceptors. Both compounds equipotent agonists at adrenoceptors as assessed in functional studies isolated organs radioligand binding studies. In addition, clonidine possess the same degree selectivity for over alpha-1 after intracisternal administration to spontaneously hypertensive rats, consistent with observations made vitro that both adrenoceptor agonists. were...
The GEMINI long-term safety [LTS] study is a continuing phase 3 trial investigating the and efficacy of vedolizumab, an α4β7 integrin antagonist for ulcerative colitis [UC] Crohn’s disease. We provide interim analysis in patients with UC. Patients from C13004 1 studies cohort vedolizumab-naïve received open-label vedolizumab every 4 weeks. Interim data were collected May 22, 2009 to June 27, 2013. Clinical response remission, evaluated using partial Mayo scores, health-related quality life...
Vedolizumab is a gut-selective α4β7 integrin antagonist therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial an ongoing open-label study investigating the of vedolizumab. We present interim exploratory analyses efficacy in patients with Patients from C13004, 2 3 studies vedolizumab-naïve could enrol LTS received vedolizumab every 4 weeks. Data were collected May 22, 2009 to June 27, 2013. Outcomes clinical response remission, defined by Harvey-Bradshaw...
Background & AimsThe efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal antibody against the integrin α4β7, were demonstrated in multicenter, phase 3, randomized, placebo-controlled trials patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease. We analyzed data from 1 these determine effects vedolizumab therapy UC, based on past exposure anti–tumor necrosis factor-α (TNF) antagonists.MethodsWe performed post hoc analysis GEMINI study,...
The International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) is only global organization devoted to study and management inflammatory bowel diseases (IBDs), namely, Crohn's disease ulcerative colitis. Membership composed physician-scientists who have established expertise in these diseases. hosts an annual meeting a number working groups addressing issues epidemiology IBD, diet nutrition, development use treatments IBD. There are currently 89 members IOIBD representing...
The COVID-19 pandemic has claimed the lives of nearly 2 million people worldwide.1 Following rapid sequencing SARS-CoV-2, pharmaceutical companies and academic institutions rapidly generated vaccine candidates on back a variety both established novel platforms.2–4 Vaccines accelerated at unprecedented pace to phase 3 development, in December 2020, two mRNA vaccines one inactivated were authorised for use number countries. Additional platforms are late stages testing.5 Prioritisation access...
Guselkumab, a selective p19 interleukin-23 antagonist, is approved for the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated efficacy safety guselkumab in patients with moderately to severely active Crohn's disease inadequate response or intolerance conventional biologic therapy.GALAXI-1, phase 2, double-blind, placebo-controlled study, randomized 1:1:1:1:1 intravenous 200 mg, 600 1200 mg at weeks 0, 4, 8; ustekinumab approximately 6 mg/kg week 0 90 subcutaneously...